All EDQM facilities are open and all activities and operations are progressing normally.

In early 2020, the EDQM quickly established a business continuity plan to anticipate and mitigate any risks of disruption to its activities caused by the COVID-19 pandemic. This ensured that the standards necessary for the production and release of medicines by pharmaceutical manufacturers and for market surveillance testing by Official Medicines Control Laboratories (OMCLs) remained available. Specific measures were also taken to ensure the granting and revision of certificates of suitability (CEPs).

The measures implemented during the initial lock-down in the spring of 2020 proved to be effective and efficient. EDQM working methods remain flexible, and staff not essential to operations on-site have been working remotely to varying degrees since then. The EDQM continues to monitor the situation and the health and safety regulations in force in France, the EDQM’s host country.